VAMAS1
MCID: VTL004
MIFTS: 54

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 (VAMAS1) malady

Categories: Genetic diseases, Rare diseases, Skin diseases, Immune diseases

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Aliases & Descriptions for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 54 24 29 13 38 69
Vitiligo 38 12 50 24 25 54 66 29 52 41 42 14 69
Vtlg 24 25 66
Generalized Vitiligo 66 69
Vamas1 24 66
Slev1 24 66
Vitiligo-Associated Multiple Autoimmune Disease 1 66
Ssytemic Lupus Erythematosus, Vitiligo-Related 24
Systemic Lupus Erythematosus Vitiligo-Related 66

Characteristics:

HPO:

32
vitiligo-associated multiple autoimmune disease susceptibility 1:
Inheritance polygenic inheritance


Classifications:



External Ids:

OMIM 54 606579
Disease Ontology 12 DOID:12306
ICD10 33 L80
ICD9CM 35 709.01
NCIt 47 C26915
SNOMED-CT 64 156437000 56727007
UMLS 69 C0042900

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

NIH Rare Diseases : 50 vitiligo is a pigmentation disorder in which melanocytes (the cells that make pigment) in the skin are destroyed. as a result, white patches appear on the skin in different parts of the body, and sometimes also on both the mucous membranes and the retina. the average age of onset is in the mid-20s. it is generally considered to be an autoimmune disorder, and about 20-25 percent of people with vitiligo also have at least one other autoimmune disorder. in the absence of other conditions, vitiligo does not affect general health; however, concerns about appearance and ethnic identity are significant issues for many affected individuals. the exact cause of vitiligo is not known, but there are several different theories. there is strong evidence that people with vitiligo inherit a group of genes that make them susceptible to depigmentation. the main goal of treating vitiligo is to improve appearance; current treatment options include medication, surgery, and adjunctive therapies (used along with surgical or medical treatments). last updated: 11/20/2012

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1, also known as vitiligo, is related to deafness, congenital, with vitiligo and achalasia and alopecia universalis onychodystrophy vitiligo, and has symptoms including vitiligo, nevus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 is NLRP1 (NLR Family Pyrin Domain Containing 1), and among its related pathways/superpathways are NF-kappaB Signaling and Wnt Signaling Pathways: beta-Catenin-independent Wnt/Ca2+ Signaling and Other Non-canonical Wnt Signaling Pathways. The drugs Pimecrolimus and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and thyroid, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A hypersensitivity reaction type II disease that causes depigmentation of patches of skin resulting from loss of function or death of melanoctyes.

Genetics Home Reference : 25 Vitiligo is a condition that causes patchy loss of skin coloring (pigmentation). The average age of onset of vitiligo is in the mid-twenties, but it can appear at any age. It tends to progress over time, with larger areas of the skin losing pigment. Some people with vitiligo also have patches of pigment loss affecting the hair on their scalp or body.

OMIM : 54 Generalized vitiligo is an autoimmune disease characterized by melanocyte loss, which results in patchy depigmentation... (606579) more...

MedlinePlus : 41 vitiligo causes white patches on your skin. it can also affect your eyes, mouth, and nose. it occurs when the cells that give your skin its color are destroyed. no one knows what destroys them. it is more common in people with autoimmune diseases, and it might run in families. it usually starts before age 40. the white patches are more common where your skin is exposed to the sun. in some cases, the patches spread. vitiligo can cause your hair to gray early. if you have dark skin, you may lose color inside your mouth. using sunscreen will help protect your skin, and cosmetics can cover up the patches. treatments for vitiligo include medicines, light therapy, and surgery. not every treatment is right for everyone. many have side effects. some take a long time. some do not always work. nih: national institute of arthritis and musculoskeletal and skin diseases

UniProtKB/Swiss-Prot : 66 Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases. Vitiligo-associated multiple autoimmune disease 1: A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.

Wikipedia : 71 Vitiligo is a long term skin condition characterized by patches of the skin losing their pigment. The... more...

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 232)
id Related Disease Score Top Affiliating Genes
1 deafness, congenital, with vitiligo and achalasia 12.1
2 alopecia universalis onychodystrophy vitiligo 11.8
3 vitiligo mental retardation facial dysmorphism uremia 11.8
4 autoimmune disease 1 11.4
5 alopecia areata 11.4
6 piebaldism 11.1
7 vogt-koyanagi-harada disease 11.1
8 autoimmune atrophic gastritis 11.0
9 spastic paraplegia 23 11.0
10 alezzandrini syndrome 11.0
11 schrander-stumpel theunissen hulsmans syndrome 10.9
12 autoimmune polyglandular syndrome type 3 10.9
13 stiff-person syndrome 10.9
14 autoimmune polyendocrinopathy syndrome , type i, with or without reversible metaphyseal dysplasia 10.7
15 hemifacial atrophy, progressive 10.7
16 lelis syndrome 10.7
17 immunodeficiency 7, tcr-alpha/beta deficient 10.7
18 melanoma, cutaneous malignant 8 10.3 MITF TYR
19 verrucous papilloma 10.3 MITF PMEL TYR
20 complement component 8 deficiency 10.3 AIRE CTLA4 PTPN22
21 epilepsy, progressive myoclonic 5 10.3 MITF TYR
22 aicardi-goutieres syndrome 6 10.2 MITF TYR TYRP1
23 gallbladder disease 10.2 POMC TYR TYRP1
24 malignant otitis externa 10.2 AIRE POMC PTPN22
25 hashimoto's encephalitis 10.2 MLANA PMEL TYR
26 noonan-like syndrome with loose anagen hair 10.2 AIRE CTLA4
27 mediastinitis 10.2 MITF MLANA PMEL
28 demyelinating disease 10.2 MLANA PMEL TYR
29 periodontosis 10.2 AIRE CTLA4 PTPN22
30 ovarian surface papilloma 10.2 MLANA PMEL TYR
31 conjunctivitis with pseudomembrane 10.2 CAT TPO
32 portal vein thrombosis 10.2 MLANA PMEL TYR
33 intracranial embolism 10.2 MITF MLANA TYR
34 neutral lipid storage disease with myopathy 10.2 CTLA4 PTPN22
35 external ear basal cell carcinoma 10.2 MITF MLANA TYR
36 anterior corneal pigmentation 10.2 NLRP1 PMEL PTPN22 TYR TYRP1
37 charcot-marie-tooth neuropathy, x-linked recessive, 2 10.2 KITLG MITF
38 myopathy of extraocular muscle 10.2 KITLG MITF TYR TYRP1
39 denys-drash syndrome 10.2 AIRE CTLA4 PTPN22 TPO
40 janus kinase-3 deficiency 10.2 AIRE CTLA4 PTPN22 TPO
41 nelson syndrome 10.2 MLANA PMEL TYR
42 lattice corneal dystrophy 10.2 FGF2 MITF PMEL TYR
43 alopecia 10.2
44 vaginal yolk sac tumor 10.2 CTLA4 MLANA TYR
45 melanoma 10.2
46 retroperitoneal leiomyosarcoma 10.2 CTLA4 MLANA TYR
47 thyroiditis 10.1
48 diabetes mellitus, insulin-dependent, 12 10.1 AIRE CTLA4 PTPN22 TPO
49 pseudo-gaucher disease 10.1 CAT GCH1 PCBD1
50 articulation disorder 10.1 AIRE CTLA4 PTPN22 TPO

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Symptoms by clinical synopsis from OMIM:

193200

Clinical features from OMIM:

606579 193200

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

32
id Description HPO Frequency HPO Source Accession
1 vitiligo 32 HP:0001045
2 nevus 32 HP:0003764

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:


exanthema, pruritus

MGI Mouse Phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 TYR TYRP1 AIRE C4B CAT CTLA4
2 hematopoietic system MP:0005397 10.2 AIRE C4B CTLA4 FGF2 KITLG MITF
3 cardiovascular system MP:0005385 10.15 C4B CTLA4 DDC FGF2 KITLG MCHR1
4 immune system MP:0005387 10.14 AIRE C4B CTLA4 DDC KITLG MITF
5 mortality/aging MP:0010768 10.13 AIRE C4B CAT CTLA4 DDC FGF2
6 integument MP:0010771 10.07 CTLA4 DCT KITLG MITF MLANA PCBD1
7 hearing/vestibular/ear MP:0005377 9.95 TYR TYRP1 FGF2 KITLG MITF TPO
8 nervous system MP:0003631 9.85 POMC TYR TYRP1 AIRE DCT DDC
9 neoplasm MP:0002006 9.8 TYR TYRP1 AIRE CAT FGF2 KITLG
10 pigmentation MP:0001186 9.65 CTLA4 DCT KITLG MITF MLANA PCBD1
11 vision/eye MP:0005391 9.36 AIRE DCT DDC FGF2 KITLG MITF

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pimecrolimus Approved, Investigational Phase 4,Phase 2 137071-32-0 6447131 17753757
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
3
Acetylcholine Approved Phase 4 51-84-3 187
4
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
5
Hydroquinone Approved Phase 4 123-31-9 785
6
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3 9004-61-9 53477741 24759
7
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
8
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
9 Analgesics Phase 4,Phase 2
10 Analgesics, Non-Narcotic Phase 4,Phase 2
11 Anti-Allergic Agents Phase 4
12 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
14 Antirheumatic Agents Phase 4,Phase 2,Phase 1
15 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2
16 Dermatologic Agents Phase 4,Phase 2
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 mometasone furoate Phase 4 83919-23-7
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
20 Anti-Asthmatic Agents Phase 4
21 Autonomic Agents Phase 4
22 Bronchodilator Agents Phase 4
23
Fluticasone Phase 4 90566-53-3, 80474-14-2 62924 22833648
24 Respiratory System Agents Phase 4
25 Amotosalen Phase 4,Phase 2
26 Ficusin Phase 4,Phase 2
27 Furocoumarins Phase 4,Phase 2
28 glucocorticoids Phase 4,Phase 2,Phase 3
29 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
30 Hormones Phase 4,Phase 2,Phase 3,Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
32 abobotulinumtoxinA Phase 4
33 Botulinum Toxins Phase 4
34 Botulinum Toxins, Type A Phase 4
35 Cholinergic Agents Phase 4
36 incobotulinumtoxinA Phase 4
37 Neuromuscular Agents Phase 4
38 Neurotransmitter Agents Phase 4
39 onabotulinumtoxinA Phase 4
40 Pharmaceutical Solutions Phase 4,Phase 2
41 Antioxidants Phase 4
42 Keratolytic Agents Phase 4
43 Protective Agents Phase 4,Phase 3
44 Radiation-Protective Agents Phase 4
45 Hylan Phase 4
46
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
47 triamcinolone acetonide Phase 2, Phase 3
48 Triamcinolone diacetate Phase 2, Phase 3
49 Triamcinolone hexacetonide Phase 2, Phase 3
50 Anesthetics Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 86)
id Name Status NCT ID Phase
1 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4
2 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4
3 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4
4 Punchgrafting Techniques for Vitiligo Unknown status NCT01377077 Phase 4
5 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients Unknown status NCT01640678 Phase 4
6 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4
7 NB-UVB and PUVA Vitiligo Study Completed NCT01732965 Phase 4
8 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients Completed NCT02458417 Phase 4
9 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4
10 A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. Completed NCT00293163 Phase 4
11 Safety Study of Cosmetic Tissue Augmentation in People of Color Completed NCT01147172 Phase 4
12 Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI Completed NCT00891774 Phase 4
13 Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo Terminated NCT02506101 Phase 4
14 Topical Bimatoprost Solution 0.03%in Stable Vitiligo Withdrawn NCT01202513 Phase 4
15 Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol Unknown status NCT00525395 Phase 3
16 Vitiligo Skin Transplantation Completed NCT00830713 Phase 3
17 Excimer Lamp Versus Excimer Laser in Vitiligo Treatment Completed NCT00696358 Phase 3
18 Epidermal Cell Transplantation in Vitiligo Skin Completed NCT01629979 Phase 2, Phase 3
19 Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo Completed NCT00807690 Phase 3
20 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
21 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3
22 Emervel Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds Completed NCT01205061 Phase 3
23 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Recruiting NCT02191748 Phase 2, Phase 3
24 Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC Recruiting NCT02466997 Phase 3
25 A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Recruiting NCT02156427 Phase 3
26 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) Recruiting NCT02608450 Phase 3
27 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control Terminated NCT01841008 Phase 2, Phase 3
28 Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3
29 Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
30 Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo Unknown status NCT01766609 Phase 2
31 Efficacy of Red Light in Vitiligo Unknown status NCT01787708 Phase 2
32 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
33 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
34 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand Unknown status NCT01792245 Phase 2
35 Melanocyte Transplantation for Patients With Stable Vitiligo. Completed NCT01701648 Phase 1, Phase 2
36 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2
37 Clinical Trial of Simvastatin to Treat Generalized Vitiligo Completed NCT01517893 Phase 2
38 Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo Completed NCT00134368 Phase 2
39 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2
40 Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Completed NCT00372307 Phase 2
41 Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients Completed NCT00928902 Phase 2
42 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO Recruiting NCT03036995 Phase 2
43 A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Recruiting NCT03099304 Phase 2
44 Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Recruiting NCT03123016 Phase 2
45 Topical Ruxolitinib for the Treatment of Vitiligo Active, not recruiting NCT02809976 Phase 2
46 Atorvastatin in Active Vitiligo Active, not recruiting NCT02432534 Phase 2
47 Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo Terminated NCT01923142 Phase 2
48 A New Micrografting Technique for Vitiligo Terminated NCT01262547 Phase 2
49 Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model Unknown status NCT00172939 Phase 1
50 Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents Completed NCT00907062 Phase 1

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:
JACE
Embryonic/Adult Cultured Cells Related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:
Cultured epidermis (JACE PMIDs: 23265935 17465819 11987545

Cochrane evidence based reviews: vitiligo

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Genetic tests related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

id Genetic test Affiliating Genes
1 Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 29 24 NLRP1
2 Vitiligo 29

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

39
Skin, Eye, Thyroid, Retina

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

66
id Symbol AA change Variation ID SNP ID
1 NLRP1 p.Leu155His VAR_033239 rs12150220
2 PTPN22 p.Arg620Trp VAR_022605 rs2476601

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 NLRP1 NM_001033053.2(NLRP1): c.464T> A (p.Leu155His) single nucleotide variant risk factor rs12150220 GRCh37 Chromosome 17, 5485367: 5485367

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1.

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Cellular components related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 melanosome membrane GO:0033162 9.13 DCT TYR TYRP1
2 melanosome GO:0042470 9.02 DCT MLANA PMEL TYR TYRP1

Biological processes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.8 CAT DCT PCBD1 TPO TYR TYRP1
2 melanosome organization GO:0032438 9.49 PMEL TYRP1
3 hydrogen peroxide catabolic process GO:0042744 9.48 CAT TPO
4 melanocyte differentiation GO:0030318 9.46 MITF TYRP1
5 embryonic hemopoiesis GO:0035162 9.43 KITLG TPO
6 developmental pigmentation GO:0048066 9.4 DCT PMEL
7 dopamine biosynthetic process GO:0042416 9.37 DDC GCH1
8 tetrahydrobiopterin biosynthetic process GO:0006729 9.26 GCH1 PCBD1
9 pigmentation GO:0043473 9.26 DCT MITF TYR TYRP1
10 melanin biosynthetic process from tyrosine GO:0006583 9.16 DCT TYR
11 melanin biosynthetic process GO:0042438 8.92 DCT PMEL TYR TYRP1

Molecular functions related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.35 CAT DCT TPO TYR TYRP1
2 copper ion binding GO:0005507 8.8 DCT TYR TYRP1

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....